Celcuity Inc. has submitted a supplemental New Drug Application (sNDA) to the FDA for REVTORPYK (gedatolisib) for a specific type of advanced breast cancer. This filing is a significant step towards potential market approval and commercialization for the drug, representing a major milestone for the company.
Celcuity Inc. announced the submission of its supplemental New Drug Application (sNDA) to the FDA for REVTORPYK (gedatolisib). This sNDA is for the treatment of patients with HR+, HER2- advanced breast cancer with a PIK3CA mutation, who have progressed after endocrine therapy. This filing is a critical regulatory milestone, indicating that the company believes it has sufficient data to support the drug's efficacy and safety for this indication. For traders, this represents a significant short-term catalyst, as FDA acceptance and subsequent approval could lead to substantial revenue generation for Celcuity, driving its stock price higher. The long-term implication is the potential for REVTORPYK to become a new treatment option in a specific breast cancer population, offering a new revenue stream for the company. The key opportunity for traders is the potential for a positive FDA decision, while the risk lies in potential delays or rejection of the sNDA.